ProQR Therapeutics N.V. Overview
Pro stress-test →ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform. The company focuses on developing treatments for severe genetic rare diseases with significant unmet medical needs.
Strategic Profile
Pro stress-test →Eli Lilly and Company is both an existing shareholder and strategic partner. AX-0810 is advancing in cholestatic diseases with biliary atresia as the lead phase II indication, while next-generation programs like AX-0811 and AX-0422 show strong preclinical results.
Competitive Landscape
Pro stress-test →ProQR competes in the RNA therapeutics space for severe genetic rare diseases using its proprietary Axiomer RNA base-editing platform. Key therapeutic competitors include other RNA/gene therapy developers targeting inherited metabolic and monogenic disorders. The company's differentiation hinges on its editing technology and Eli Lilly partnership validation.
Industry Context
ProQR Therapeutics N.V. operates in RNA editing therapeutics.
Key facts
Founded: 2012 · Headquarters: Cambridge, MA, US · Employees: 187 · Market cap: $~179M